Abstract
Dendritic cells are the most professional antigen-presenting cells to elicit T-cellular responses toward microbial agents and cancer cells. The graft-versus-leukemia effect observed after allogeneic stem cell transplantation strongly suggests that T lymphocytes play a major role in the rejection of leukemic cells. This graft-versus-leukemia effect might be enhanced through dendritic cell vaccination. The characterization of leukemia-specific antigens eliciting immune responses in the autologous host has prompted researchers and clinicians to broaden the spectrum of dendritic cell vaccines to hematological malignancies. Recently, the focus is on acute myeloid leukemia and chronic lymphocytic leukemia. This review summarizes data on the administration of autologous and allogeneic dendritic cells to leukemia patients as an interesting approach in cellular therapy of leukemias.
MeSH terms
-
Acute Disease
-
Animals
-
Antigen Presentation
-
Bone Marrow Cells / cytology
-
Bone Marrow Cells / drug effects
-
Cancer Vaccines / adverse effects
-
Cancer Vaccines / immunology
-
Cancer Vaccines / therapeutic use*
-
Cell Adhesion
-
Cell Differentiation / drug effects
-
Cells, Cultured / immunology
-
Cells, Cultured / transplantation
-
Clinical Trials as Topic
-
Cytokines / pharmacology
-
Dendritic Cells / immunology
-
Dendritic Cells / transplantation*
-
Humans
-
Immunophenotyping
-
Immunotherapy, Active* / adverse effects
-
Immunotherapy, Active* / methods
-
Leukemia / therapy*
-
Leukemia, Lymphocytic, Chronic, B-Cell / therapy
-
Leukemia, Myeloid / therapy
-
Lymphocyte Activation
-
Mice
-
Models, Immunological
-
Neoplastic Stem Cells / cytology
-
Neoplastic Stem Cells / drug effects
-
T-Lymphocyte Subsets / immunology
-
Transplantation, Autologous
-
Transplantation, Homologous
-
Treatment Outcome
Substances
-
Cancer Vaccines
-
Cytokines